Lantern Pharma Inc. Employee Benefit and Share-based Payment Arrangement, Noncash
Lantern Pharma Inc. (LTRN) reported Employee Benefit and Share-based Payment Arrangement, Noncash of $262.92 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Cash Flow › Operating Activities
us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash · last filed 2026-05-15
- Lantern Pharma Inc. employee benefit and share-based payment arrangement, noncash for the quarter ending 2026-03-31 was $262.92K, a 77.95% increase year-over-year.
- Lantern Pharma Inc. employee benefit and share-based payment arrangement, noncash for the quarter ending 2025-12-31 was $198.82K, a 30.36% decline year-over-year.
- Lantern Pharma Inc. employee benefit and share-based payment arrangement, noncash for the quarter ending 2025-09-30 was $143.69K, a 19.80% decline year-over-year.
- Lantern Pharma Inc. employee benefit and share-based payment arrangement, noncash for the quarter ending 2025-06-30 was $160.63K, a 19.72% increase year-over-year.
- Lantern Pharma Inc. employee benefit and share-based payment arrangement, noncash for fiscal 2025 was $650.88K, a 11.19% decline from fiscal 2024.
- Lantern Pharma Inc. employee benefit and share-based payment arrangement, noncash for fiscal 2024 was $732.89K, a 31.35% decline from fiscal 2023.
- Lantern Pharma Inc. employee benefit and share-based payment arrangement, noncash for fiscal 2023 was $1.07M.
| Period end | Employee Benefit and Share-based Payment Arrangement, Noncash 3 month | Employee Benefit and Share-based Payment Arrangement, Noncash 6 month | Employee Benefit and Share-based Payment Arrangement, Noncash 9 month | Employee Benefit and Share-based Payment Arrangement, Noncash 12 month |
|---|---|---|---|---|
| 2026-03-31 | $262.92K 10-Q · filed 2026-05-15 | $461.73K derived: sum of 2 quarters · filed 2026-05-15 | $605.42K derived: sum of 3 quarters · filed 2026-05-15 | $766.04K derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | $198.82K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $342.50K derived: sum of 2 quarters · filed 2026-03-30 | $503.13K derived: sum of 3 quarters · filed 2026-03-30 | $650.88K 10-K · filed 2026-03-30 |
| 2025-09-30 | $143.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $304.31K derived: sum of 2 quarters · filed 2025-11-12 | $452.06K 10-Q · filed 2025-11-12 | $737.56K derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-06-30 | $160.63K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $308.38K 10-Q · filed 2025-08-13 | $593.88K derived: sum of 3 quarters · filed 2026-05-15 | $773.04K derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-03-31 | $147.75K 10-Q · filed 2026-05-15 | $433.25K derived: sum of 2 quarters · filed 2026-05-15 | $612.41K derived: sum of 3 quarters · filed 2026-05-15 | $746.59K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $285.50K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $464.67K derived: sum of 2 quarters · filed 2026-03-30 | $598.84K derived: sum of 3 quarters · filed 2026-03-30 | $732.89K 10-K · filed 2026-03-30 |
| 2024-09-30 | $179.17K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $313.34K derived: sum of 2 quarters · filed 2025-11-12 | $447.39K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $134.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $268.23K 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $134.06K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $1.07M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |